Jan 8 (Reuters) - Allergan Plc:
* ALLERGAN PROVIDES 2018 PRELIMINARY FINANCIAL OUTLOOK FOR SELECT INCOME STATEMENT CATEGORIES AND OTHER UPDATES
* SEES 2018 GAAP NET REVENUE OF ABOUT $15 BILLION - $15.3 BILLION
* SEES 2018 GAAP PERFORMANCE LOSS PER SHARE $0.84; SEES 2018 NON-GAAP PERFORMANCE EARNINGS PER SHARE GREATER THAN OR EQUAL TO $15.25
* FY2018 EARNINGS PER SHARE VIEW $15.80, REVENUE VIEW $15.61 BILLION -- THOMSON REUTERS I/B/E/S
* SEES NO GENERIC ENTRY FOR RESTASIS PRIOR TO Q2 2018 * SEES ONGOING COST REDUCTIONS OF $300 MILLION – $400 MILLION IN 2018 FROM FISCAL 2017 NON-GAAP OPERATING EXPENSES
* ANTICIPATES FUTURE IMPACT OF TAX CUT AND JOBS ACT TO BE BROADLY NEUTRAL TO CO‘S NON-GAAP EFFECTIVE TAX RATE OVER TIME
* CONTINUES TO “PRUDENTLY DIVEST” ITS REMAINING HOLDING IN SECURITIES OF TEVA
* PLANS TO SELL REMAINING POSITION IN TEVA IN 2018 THROUGH FORWARD SALE AGREEMENTS AND/OR OPEN MARKET SALES
* SAYS “WE FACE LOSS OF EXCLUSIVITY REVENUE HEADWINDS IN 2018” Source text for Eikon: Further company coverage:
 